**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Desirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
**Impact Factor:** 12.811

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2018 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Editorial**

- 631** Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question  
*K L Winthrop, J W Baddley*

**Views on news**

- 634** How the gut inflames the joints  
*D S Pisetsky*

**Recommendation**

- 636** EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice  
*C Dejaco, S Ramiro, C Duftner, F L Besson, T A Bley, D Blockmans, E Brouwer, M A Cimmino, E Clark, B Dasgupta, A P Diamantopoulos, H Direskeneli, A Iagnocco, T Klink, L Neill, C Ponte, C Salvarani, R H J A Slart, M Whitlock, W A Schmidt*

**Clinical and epidemiological research**

- 644** Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids  
*J W Park, J R Curtis, J Moon, Y W Song, S Kim, E B Lee*
- 650** Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics  
*T Frisell, E Baecklund, K Bengtsson, D D Giuseppe, H Forsblad-d'Elia, J Asklung, on behalf of the ARTIS Study group*
- 658** Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study  
*P C Taylor, M H Schiff, Q Wang, Y Jiang, Y Zhuang, R Kurrasch, S Daga, R Rao, P P Tak, B Hsu*
- 667** Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis  
*L Van Hoovels, J Jacobs, B Vander Cruyssen, S Van den Bremt, P Verschuere, X Bossuyt*
- 678** Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis  
*L Fraenkel, W B Nowell, G Michel, C Wiedmeyer*
- 684** Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers  
*R L Cordtz, S Hawley, D Prieto-Alhambra, P Højgaard, K Zobbe, S Overgaard, A Odgaard, L E Kristensen, L Dreyer*
- 690** Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)  
*P Nash, K Ohson, J Walsh, N Delev, D Nguyen, L Teng, J J Gómez-Reino, J A Aelion, on behalf of the ACTIVE investigators*
- 699** Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial  
*D van der Heijde, X Baraliakos, K-G A Hermann, R B M Landewé, P M Machado, W P Maksymowych, O R Davies, N de Peyrecave, B Hoepken, L Bauer, T Nurminen, J Braun*
- 706** Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: *post-hoc* analysis of the Phase IIb MUSE trial of anifrolumab  
*E F Morand, T Trasieva, A Berglind, G G Illei, R Tummala*
- 714** Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis  
*R M Yeker, I Pinal-Fernandez, T Kishi, K Pak, I N Targoff, F W Miller, L G Rider, A L Mammen, for the Childhood Myositis Heterogeneity Collaborative Study Group*

MORE CONTENTS ►



EDITOR'S CHOICE



OPEN ACCESS

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008  
JMS0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>

equator  
network




When you have finished  
with this please recycle it


**720** Efficacy and safety of adrenocorticotrophic hormone gel in refractory dermatomyositis and polymyositis  
*R Aggarwal, G Marder, D C Koontz, P Nandkumar, Z Qi, C V Oddis*

**728** A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-κB-mediated autoinflammatory disease  
*F A Aeschlimann, E D Batu, S W Canina, E Go, A Gül, P Hoffmann, H L Leavis, S Ozen, D M Schwartz, D L Stone, A van Royen-Kerkof, D L Kastner, I Aksentijevich, R M Laxer*


**Basic and translational research**

**736** DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus  
 OPEN ACCESS  
*J Imgenberg-Kreuz, J Carlsson Almlöf, D Leonard, A Alexsson, G Nordmark, M-L Eloranta, S Rantapää-Dahlqvist, A A Bengtsson, A Jönsen, L Padyukov, I Gunnarsson, E Svenungsson, C Sjöwall, L Rönnblom, A-C Syvänen, J K Sandling*

**744** Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis  
*Y Zhang, S Pötter, C-W Chen, R Liang, K Gelse, I Ludolph, R E Horch, O Distler, G Schett, J H W Distler, C Dees*

**752** Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism  
 OPEN ACCESS  
*C Municio, Á Dominguez-Soto, S Fuentelsaz-Romero, A Lamana, N Montes, V D Cuevas, R G Campos, J L Pablos, I González-Álvaro, A Puig-Kröger*

**760** Drug-induced modulation of gp130 signalling prevents articular cartilage degeneration and promotes repair  
*R Shkhyan, B Van Handel, J Bogdanov, S Lee, Y Yu, M Scheinberg, N W Banks, S Limfat, A Chernostrik, C E Franciozi, M P Alam, V John, L Wu, G B Ferguson, A Nsair, F A Petrigliano, C T Vangness, K Vadel, P Bajaj, L Wang, N Q Liu, D Evseenko*

**770** Circular RNA VMA21 protects against intervertebral disc degeneration through targeting miR-200c and X linked inhibitor-of-apoptosis protein  
 OPEN ACCESS  
*X Cheng, L Zhang, K Zhang, G Zhang, Y Hu, X Sun, C Zhao, H Li, Y M Li, J Zhao*

**Letters**

**780** Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study  
*Y-M Chen, W-N Huang, Y-D Wu, C-T Lin, Y-H Chen, D-Y Chen, T-Y Hsieh*

**782** How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review  
*S Ramiro, J S Smolen, R Landewé, D van der Heijde, L Gossec*

**783** Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20)  
 OPEN ACCESS  
*C J A Duncan, E Dinnigan, R Theobald, A Grainger, A J Skelton, R Hussain, J D Willet, D J Swan, J Coxhead, M F Thomas, J Thomas, V Zamvar, M A Slatter, A J Cant, K R Engelhardt, S Hambleton*

**Corrections**

**786** Correction: *Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study*

**787** Correction: *Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles*

**Electronic pages**

**e23** GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies  
*W Tillett, A-M Orbai, A Ogdie, Y Y Leung, V Strand, D D Gladman, P J Mease, L C Coates, On Behalf of the GRAPPA OMERACT Psoriatic Arthritis working group*

**e24** Response to: 'The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillett *et al*  
*S Ramiro, J S Smolen, R B M Landewé, D van der Heijde, L Gossec*

**e25** Spontaneous hypertensive rat exhibits bone and meniscus phenotypes of osteoarthritis: is it an appropriate control for MetS-associated OA?  
*P B Chan, C Wen*

**e26** Response to: 'Spontaneous hypertensive rat exhibits bone and meniscus phenotypes of osteoarthritis: is it an appropriate control for MetS-associated OA?' by Chan and Wen  
*C Deng, A Bianchi, N Presle, D Moulin, M Koufany, C Guillaume, H Kempf, A Pizard*